Tagrisso plus chemotherapy achieves nearly four-year median overall survival in EGFR-mutated advanced lung cancer, setting new global standard in phase III trial
Products manufactured at the new Vaughan facility will support research in areas including cancer, infectious disease, mental health, and environmental safety
Program provides access to Lilly-trained artificial intelligence to help accelerate breakthrough medicines
Targeting a 10% reduction in energy and water consumption, and a 30% cut in carbon emissions across facilities by 2025
New unit boosts innovation in liposomal delivery technologies with 8,500 MT capacity and export-ready production
Vonvendi is the only recombinant Von Willebrand factor replacement therapy with approved indications in adults and children with VWD
It will focus on interface between API and formulation manufacturing, reducing carbon footprint in formulation production, creating intellectual property, training next-generation scientists, and setting new industry benchmarks
These licenses are given in areas of infectious disease diagnostics, immunodiagnostics, and vaccine development
Now integrates with Abbott’s instinct sensor and approved for type 2 diabetes
Subscribe To Our Newsletter & Stay Updated
